BioAtla Inc.

0.28
-0.02 (-6.64%)
At close: Apr 04, 2025, 3:59 PM
0.31
10.64%
After-hours: Apr 04, 2025, 04:28 PM EDT

Company Description

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.

Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer.

It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer.

BioAtla, Inc. was founded in 2007 and is based in San Diego, California.

BioAtla Inc.
BioAtla Inc. logo
Country United States
IPO Date Dec 16, 2020
Industry Biotechnology
Sector Healthcare
Employees 65
CEO Dr. Jay M. Short Ph.D.

Contact Details

Address:
11085 Torreyana Road
San Diego, California
United States
Website https://www.bioatla.com

Stock Details

Ticker Symbol BCAB
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001826892
CUSIP Number 09077B104
ISIN Number US09077B1044
Employer ID 85-1922320
SIC Code 2836

Key Executives

Name Position
Dr. Jay M. Short Ph.D. Co-Founder, Chief Executive Officer & Chairman
Richard A. Waldron Senior Vice President & Chief Financial Officer
Christian J. Vasquez CPA Chief Accounting Officer, Controller and Corporate Secretary
Dr. Cathy Chang Ph.D. Senior Vice President of Research & Development
Dr. Eric L. Sievers M.D. Chief Medical Officer
Dr. Gerhard Frey Ph.D. Senior Vice President of Technology Development
Lisa M. Pelton Accounting Manager
Monica Sullivan Senior Vice President of Intellectual Property & Contracts
Sheri Lydick Chief Commercial Officer
Susie Melody Senior Vice President of Human Resources

Latest SEC Filings

Date Type Title
Mar 28, 2025 S-8 Filing
Mar 28, 2025 10-K Annual Report
Mar 27, 2025 8-K Current Report
Mar 18, 2025 SCHEDULE 13G Filing
Mar 14, 2025 8-K Current Report
Mar 13, 2025 4 Filing
Mar 13, 2025 4 Filing
Mar 13, 2025 4 Filing
Mar 13, 2025 4 Filing
Feb 24, 2025 4 Filing